Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients

Patients with metastatic colorectal cancer (mCRC) who have received all approved standard treatments (except Regorafenib and TAS 102) no longer have treatment options available while maintaining a good performance status which would allow them to receive a new treatment

  • 25 views
  • 20 May, 2021
  • 12 locations
Prospective Evaluation of Hypofractionated Stereotactic RT Using CyberKnife for Patients With Prostate Cancer

The main purpose of study is to evaluate hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients with low and intermediate risk of progression prostate cancer.

metastasis
adenocarcinoma of prostate
adenocarcinoma
  • 4 views
  • 23 Jan, 2021
  • 1 location
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage

The purpose of this study is to To confirm the predictive value of CCND1 for TPF induction in cN2 patients with OSCC

induction chemotherapy
oral cavity cancer
squamous cell carcinoma of the oral cavity
carcinoma of oral cavity
carcinoma
  • 19 views
  • 24 Jan, 2021
  • 1 location
Anastrozole Palbociclib Trastuzumab and Pertuzumab in HR-positive HER2-positive Metastatic Breast

and all biologic approach to the treatment of HR+, HER2+ metastatic breast cancer. Additionally, the researchers aim to examine potential biomarkers of response to palbociclib including cyclin D1

metastasis
stage iv breast cancer
anastrozole
tamoxifen
ejection fraction
  • 38 views
  • 09 Jul, 2021
  • 7 locations
A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer

biomarkers than those who receive placebo. Cyclin D1 will serve as the primary biomarker. This investigation will determine whether subjects randomized to UAB30 have an increase in all trans-retinoic

fasting
skin cancer
cancer
melanoma skin
all trans-retinoic acid
  • 0 views
  • 26 Jan, 2021
  • 1 location
Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma

mechanisms have been described: (i) Amplification or overexpression of cyclin D1, (ii) Amplification of CDK4, (iii) Activating mutation of CDK4, and (iv) Loss of the CDK4 inhibitor, p16 (CDKN2A). Human

intensity-modulated radiation therapy
dental caries
squamous cell carcinoma of head and neck
squamous cell carcinoma of the oral cavity
carcinoma
  • 82 views
  • 25 Jan, 2021
  • 1 location
CDK4/6 Tumor Abemaciclib Paclitaxel

cancer cell proliferation. Cyclin D1 acts with CDK4 and CDK6 to phosphorylate Rb and promote cell-cycle progression, and CDK4/6 inhibitor might be effective for the patients with CCND1/2/3

  • 0 views
  • 01 May, 2021
  • 1 location
A Study of Abemaciclib in Recurrent Glioblastoma

This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM). The following intervention will be used in this study: -Abemaciclib

corticosteroids
recurrent tumor
residual tumor
astrocytoma
stereotactic biopsy
  • 335 views
  • 11 Aug, 2021
  • 7 locations
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

This is a single-arm, phase II study that will enroll a total of 45 subjects. All subjects will have a confirmed diagnosis of metastatic or unresectable soft tissue sarcoma or bone sarcoma. All subjects must have intact Rb, identified at the time of screening, by immunohistochemistry testing of submitted tumor …

metastasis
cancer chemotherapy
immunomodulators
neutrophil count
blood transfusion
  • 0 views
  • 23 Feb, 2021
  • 3 locations
Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer

This early phase I trial studies how well abemaciclib and letrozole work in treating patients with endometrial cancer and determines whether there are changes in patients' cancer cell biomarkers (a genetic feature or specific protein) for cell growth before and after treatment. Antihormone therapy with aromatase inhibitors, such as letrozole, …

  • 2 views
  • 15 May, 2021
  • 2 locations